BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, January 30, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 2018

View Archived Issues

Astrocyte-driven inflammation is depression biomarker, target

Read More

Fungus is no fun for asthmatics

Read More

Senescent cells tangle up tau

Read More

PFN2 and GAMT are novel biomarkers of Charcot-Marie-Tooth disease

Read More

Methylation of the tumor suppressor TIPE3 corresponds to worse prognosis in nasopharyngeal carcinoma

Read More

Autoantibodies against TSP-4 are a diagnostic feature of osteoarthritis

Read More

Gilead Sciences presents the discovery of a novel Cyp inhibitor with potent anti-HCV activity

Read More

Phase I/II clinical trial of OT-58 recruiting patients with CBSDH

Read More

Sareum selects small-molecule inhibitor of TYK2/JAK1 for development for certain cancers

Read More

AI-powered platform for optimization of drug combination regimen in metastatic prostate cancer

Read More

Novavax opens phase II trial of NanoFlu

Read More

Vaccibody presents positive 6-month interim results from phase I/IIa study of VB10.16 immunotherapy

Read More

Eli Lilly and Company patents MAP3K5 inhibitors

Read More

Prelude Therapeutics divulges new PRMT5 inhibitors

Read More

Aldeyra announces positive data from phase IIb study of reproxalap topical ophthalmic solution

Read More

3M Pharmaceuticals synthesizes new cytokine biosynthesis inducers

Read More

Lupin identifies SCN9A blockers

Read More

Patient recruitment starts in phase III study of Ameluz plus BF-RhodoLED in superficial BCC

Read More

Lycera patents RORC agonists as IL-17 production enhancers

Read More

PAF-R antagonist XQ-1H well tolerated in phase I study

Read More

BriaCell achieves proof of concept with Bria-IMT in phase IIa breast cancer study

Read More

Newly developed ISOD mouse model mimics human disease

Read More

Janssen initiates phase III trial of guselkumab in pediatric psoriasis

Read More

Concert Pharmaceuticals amends protocol of phase IIa trial with CTP-543 in alopecia areata

Read More

Targovax reports interim tumor response data from phase I study of ONCOS-102 in advanced melanoma

Read More

MKP-5 inhibition as a novel therapeutic target for lung fibrosis

Read More

Discovery of novel Ref-1 inhibitors with the ability to block ocular neovascularization

Read More

Researchers develop viable murine model of cblC deficiency

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 29, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 29, 2026.
  • DNA mutations or genetic disorder concept art

    Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

    BioWorld Science

    Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Centessa’s CNT-9982 shows promise for MDD

    BioWorld Science
    Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing